Haisen Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 65.7354 million yuan, up 8.13% from the same period last year. Total operating revenue was 251 million yuan, up 3.64% year-on-year, marking a third consecutive year of growth. Net cash inflow from operating activities was 75.4652 million yuan, up 1.53% year-on-year. The company's latest gross margin was 46.58%, up 2.05 percentage points year-on-year, achieving a fourth consecutive year of increase. The latest asset-liability ratio was 6.91%, down 1.38 percentage points year-on-year.
Zhejiang Haisen Pharmaceutical Co. Ltd. ANet profit up 8.13% and revenue up 3.64% in interim report